Key result
Administration of α-galactosylceramide significantly improved 28-day survival compared to PBS (59% vs 32%, P<0.05) and attenuated left ventricular remodeling in mice after myocardial infarction.
Why the study?
Does activation of iNKT cells with α-galactosylceramide improve survival and attenuate LV remodeling in mice after myocardial infarction?
Population
Mice with induced myocardial infarction (n=58 for main experiment) and iNKT cell-deficient Jα18(-/-) mice
Comparison
Injection of α-galactosylceramide 1 and 4 days… vs Phosphate-buffered saline injection 1 and 4 days…
Design
Preclinical
Follow-up
28 days
Authors
Loading...
Hypothesis-generating for iNKT activation post-MI; leaves open translation to human therapy.
Does activation of iNKT cells with α-galactosylceramide improve survival and attenuate LV remodeling in mice after myocardial infarction?
Absolute Event Rate: 59% vs 32%
p-value: p=<0.05
Activation of iNKT cells with α-galactosylceramide improves survival and attenuates post-infarct LV remodeling in mice, mediated by enhanced IL-10 expression.
Sobirin et al. (2012) studied Myocardial infarction (n=58). α-galactosylceramide (αGC) vs. Phosphate-buffered saline was evaluated on Survival rate (p=<0.05). Administration of α-galactosylceramide significantly improved 28-day survival compared to PBS (59% vs 32%, P<0.05) and attenuated left ventricular remodeling in mice after myocardial infarction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: